ijms-logo

Journal Browser

Journal Browser

Emerging Concepts and Novel Therapeutics to Overcome Treatment Resistance in Prostate Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 9201

Special Issue Editors


E-Mail Website
Guest Editor
Departments of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Interests: prostate cancer; taxane chemotherapy; antiandrogens; novel therapeutic targets; therapeutic resistance; epithelial-mesenchymal transition; apoptosis; molecular signatures; cell lineage
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Urology, Mayo Clinic, Rochester, MN, USA
Interests: prostate cancer; cancer cell invasion; drug resistance; proteomics; extracellular vesicles; metastasis

Special Issue Information

Dear Colleagues,

Recently, a number of novel therapeutic agents have been developed for the treatment of advanced prostate cancer, including second-generation androgen-deprivation therapy, radionuclide therapy, PARP inhibitors, stereotactic body radiotherapy, and more recently, immunotherapy. While these treatments lead to improvements in overall survival, they have limited curative efficacy. Progress in characterizing the molecular landscape of metastatic prostate cancer has allowed important insights into mechanisms of therapeutic resistance against, and tumor progression towards lethal disease. For instance, lineage plasticity and neuroendocrine dedifferentiation have emerged as important mechanisms of resistance to androgen-deprivation therapy in prostate cancer. There is a critical need to understand the underpinnings of acquired resistance and develop rationalized therapeutic approaches for the treatment of prostate cancer.

This Special Issue of the International Journal of Molecular Sciences welcomes both original research articles and review papers addressing the molecular mechanisms involved in therapeutic resistance, lineage plasticity, and phenotypic reprogramming, leading to prostate cancer recurrence and, ultimately, lethal disease. We are particularly interested in manuscripts addressing molecular markers of treatment failure in prostate cancer patients, new molecular tools to overcome therapeutic resistance, and the development of novel therapeutics efficiently targeting metastatic tumors in pre-clinical models.

Prof. Dr. Natasha Kyprianou
Dr. Fabrice Lucien-Matteoni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Prostate cancer
  • Therapeutic resistance
  • Lineage plasticity
  • Neuroendocrine phenotype
  • Androgen receptor
  • Phenotypic reprogramming
  • Novel targets
  • Epigenetics
  • Molecular signatures

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 175 KiB  
Editorial
Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer
by Natasha Kyprianou and Fabrice Lucien
Int. J. Mol. Sci. 2021, 22(21), 11645; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222111645 - 28 Oct 2021
Viewed by 1461
Abstract
This Special Issue focuses on the molecular mechanisms involved in therapeutic resistance, lineage plasticity, and phenotypic reprogramming leading to prostate cancer recurrence and, ultimately, lethal disease [...] Full article

Research

Jump to: Editorial, Review

21 pages, 7896 KiB  
Article
The RelB-BLNK Axis Determines Cellular Response to a Novel Redox-Active Agent Betamethasone during Radiation Therapy in Prostate Cancer
by Luksana Chaiswing, Fangfang Xu, Yanming Zhao, Jon Thorson, Chi Wang, Daheng He, Jinpeng Lu, Sally R. Ellingson, Weixiong Zhong, Kristy Meyer, Wei Luo, William St. Clair and Daret St. Clair
Int. J. Mol. Sci. 2022, 23(12), 6409; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23126409 - 08 Jun 2022
Cited by 2 | Viewed by 3391
Abstract
Aberrant levels of reactive oxygen species (ROS) are potential mechanisms that contribute to both cancer therapy efficacy and the side effects of cancer treatment. Upregulation of the non-canonical redox-sensitive NF-kB family member, RelB, confers radioresistance in prostate cancer (PCa). We screened FDA-approved compounds [...] Read more.
Aberrant levels of reactive oxygen species (ROS) are potential mechanisms that contribute to both cancer therapy efficacy and the side effects of cancer treatment. Upregulation of the non-canonical redox-sensitive NF-kB family member, RelB, confers radioresistance in prostate cancer (PCa). We screened FDA-approved compounds and identified betamethasone (BET) as a drug that increases hydrogen peroxide levels in vitro and protects non-PCa tissues/cells while also enhancing radiation killing of PCa tissues/cells, both in vitro and in vivo. Significantly, BET increases ROS levels and exerts different effects on RelB expression in normal cells and PCa cells. BET induces protein expression of RelB and RelB target genes, including the primary antioxidant enzyme, manganese superoxide dismutase (MnSOD), in normal cells, while it suppresses protein expression of RelB and MnSOD in LNCaP cells and PC3 cells. RNA sequencing analysis identifies B-cell linker protein (BLNK) as a novel RelB complementary partner that BET differentially regulates in normal cells and PCa cells. RelB and BLNK are upregulated and correlate with the aggressiveness of PCa in human samples. The RelB-BLNK axis translocates to the nuclear compartment to activate MnSOD protein expression. BET promotes the RelB-BLNK axis in normal cells but suppresses the RelB-BLNK axis in PCa cells. Targeted disruptions of RelB-BLNK expressions mitigate the radioprotective effect of BET on normal cells and the radiosensitizing effect of BET on PCa cells. Our study identified a novel RelB complementary partner and reveals a complex redox-mediated mechanism showing that the RelB-BLNK axis, at least in part, triggers differential responses to the redox-active agent BET by stimulating adaptive responses in normal cells but pushing PCa cells into oxidative stress overload. Full article
Show Figures

Figure 1

Review

Jump to: Editorial, Research

12 pages, 553 KiB  
Review
Tadalafil and Steroid Hormones Interactions in Adipose, Bone and Prostate Tissues: Focus on Translational Perspectives
by Emanuela Alessandra Greco, Cristina Antinozzi, Luigi Di Luigi, Antonio Aversa and Paolo Sgrò
Int. J. Mol. Sci. 2022, 23(8), 4191; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23084191 - 11 Apr 2022
Cited by 1 | Viewed by 3679
Abstract
Tadalafil is a selective phosphodiesterase type-5 (PDE5) inhibitor that is approved for the treatment of men with erectile dysfunction (ED) and/or benign prostate hyperplasia (BPH) -associated symptoms. Besides its classical actions on PDE5 within the genitourinary tract, where the specific enzyme expression is [...] Read more.
Tadalafil is a selective phosphodiesterase type-5 (PDE5) inhibitor that is approved for the treatment of men with erectile dysfunction (ED) and/or benign prostate hyperplasia (BPH) -associated symptoms. Besides its classical actions on PDE5 within the genitourinary tract, where the specific enzyme expression is maximal, it may exert different systemic effects. This is mainly due to the pleiotropic distribution of PDE5 enzyme throughout the human (and animal) body, where it can exert protective effects in different clinical conditions. Recently, it has been demonstrated that tadalafil may display novel actions on androgen receptor (AR) expression and activity and cytochrome P19a1 (Cyp19a1) and estrogen receptor β (ERβ) expression in different in vitro systems, such as adipose, bone and prostate cancer cells, where it can act as a selective modulator of steroid hormone production. This may determine novel potential mechanism(s) of control in pathophysiologic pathways. In this review, we summarize basic research and translational results applicable to the use of tadalafil in the treatment of obesity, bone loss and prostate cancer. Full article
Show Figures

Figure 1

Back to TopTop